Levi & Korsinsky, LLP announces that a FREQ class action lawsuit has been filed on behalf of investors who purchased Frequency Therapeutics, Inc.  (FREQ) securities between November 16, 2020 – March 22, 2021. For more on the FREQ Lawsuit please contact us today.

According to the Frequency Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint, during the class period, Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.

TO LEARN MORE ABOUT THE FREQ CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Frequency Therapeutics you have until August 2, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com